CRISPR Therapeutics Financial Statements
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRISPR Therapeutics revenue and earnings
In fiscal 2025, CRISPR Therapeutics generated $3.5 million in revenue, down 90.6% from fiscal 2024, its first annual decline since 2024. CRISPR Therapeutics reported a net loss of $581.6 million, compared with a loss of $366.3 million a year earlier. Operating margin was -18933.6%.
Diluted earnings per share came in at -$6.47. Over the last 5 fiscal years, CRSP's revenue has grown at a 37.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
CRISPR Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.51M | 37.31M | 371.21M | 1.20M | 914.96M | 719.00K | 289.59M | 3.12M | 41.00M | 5.16M |
| Revenue growth (YoY) | -90.59% | -89.95% | +30885.48% | -99.87% | +127154.94% | -99.75% | +9169.85% | -92.38% | +693.90% | +1990.69% |
| Operating Expenses | 668.08M | 503.88M | 593.74M | 674.36M | 541.43M | 355.15M | 242.85M | 162.07M | 105.64M | 73.29M |
| Research & Development | 284.81M | 310.24M | 387.33M | 461.64M | 340.57M | 221.38M | 179.36M | 113.77M | 69.80M | 42.24M |
| Operating Income | -664.57M | -466.57M | -222.54M | -673.16M | 373.53M | -354.44M | 46.74M | -158.94M | -64.65M | -68.13M |
| Other Income (Expense) | 86.61M | 103.90M | 71.82M | 22.66M | 6.00M | 6.38M | 20.57M | -5.49M | -1.96M | 45.41M |
| Pretax Income | -577.97M | -362.67M | -150.72M | -650.50M | 379.53M | -348.06M | 67.31M | -164.43M | -66.61M | -22.72M |
| Income Tax | 3.63M | 3.59M | 2.89M | -325.00K | 1.87M | 809.00K | 448.00K | 553.00K | 1.75M | 484.00K |
| Net Income | -581.60M | -366.25M | -153.61M | -650.17M | 377.66M | -348.87M | 66.86M | -164.98M | -68.36M | -23.18M |
| Net Income growth (YoY) | — | — | — | -272.16% | — | -621.80% | — | — | — | — |
| EPS (Basic) | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 | -3.44 | -1.71 | -1.89 |
| EPS (Diluted) | -6.47 | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 | -3.44 | -1.71 | -1.89 |
| Shares Outstanding (Basic) | 89.93M | 84.36M | 79.22M | 77.75M | 75.95M | 65.95M | 54.39M | 47.96M | 40.06M | 12.26M |
| Shares Outstanding (Diluted) | 89.93M | 84.36M | 79.22M | 77.75M | 80.39M | 65.95M | 56.93M | 47.96M | 40.06M | 12.26M |
| EBITDA | -645.09M | -447.31M | -202.70M | -648.99M | 391.48M | -345.25M | 51.47M | -155.42M | -61.62M | -67.20M |
| Operating Margin | -18933.65% | -1250.38% | -59.95% | -56190.40% | 40.82% | -49295.55% | 16.14% | -5087.80% | -157.69% | -1319.33% |
| Net Margin | -16569.77% | -981.54% | -41.38% | -54271.70% | 41.28% | -48520.86% | 23.09% | -5281.08% | -166.74% | -448.82% |
This table shows 10 annual periods of CRISPR Therapeutics's income statement, from FY 2025 back to FY 2016, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow CRSP's reporting calendar. What is a income statement?